AU2015213900B2 - Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists - Google Patents
Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists Download PDFInfo
- Publication number
- AU2015213900B2 AU2015213900B2 AU2015213900A AU2015213900A AU2015213900B2 AU 2015213900 B2 AU2015213900 B2 AU 2015213900B2 AU 2015213900 A AU2015213900 A AU 2015213900A AU 2015213900 A AU2015213900 A AU 2015213900A AU 2015213900 B2 AU2015213900 B2 AU 2015213900B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- carboxylate
- hydrocarbon group
- compound according
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(*)C(CN(C)CC1)C1c1nnn[n]1 Chemical compound CC(*)C(CN(C)CC1)C1c1nnn[n]1 0.000 description 4
- RXNZFHIEDZEUQM-UHFFFAOYSA-N Brc1ncc[s]1 Chemical compound Brc1ncc[s]1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- OGXJEVCPEZGSKJ-UHFFFAOYSA-N C(CC1c2ccn[nH]2)CN1C1CCNCC1 Chemical compound C(CC1c2ccn[nH]2)CN1C1CCNCC1 OGXJEVCPEZGSKJ-UHFFFAOYSA-N 0.000 description 1
- KHHSPOJLJYEDCI-UHFFFAOYSA-N C(CC1c2nnn[nH]2)CN1C1CCNCC1 Chemical compound C(CC1c2nnn[nH]2)CN1C1CCNCC1 KHHSPOJLJYEDCI-UHFFFAOYSA-N 0.000 description 1
- YDKMMXBPUCTFTD-UHFFFAOYSA-N C(CNCC1)C1c1nnc[o]1 Chemical compound C(CNCC1)C1c1nnc[o]1 YDKMMXBPUCTFTD-UHFFFAOYSA-N 0.000 description 1
- RTDUCVVITRHYSA-LLVKDONJSA-N C(C[C@@H]1c2ncc[s]2)CN1C1CCNCC1 Chemical compound C(C[C@@H]1c2ncc[s]2)CN1C1CCNCC1 RTDUCVVITRHYSA-LLVKDONJSA-N 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1=O)=O ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- GMADLJSGNUJUCH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CCC1)CC1(F)F)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CCC1)CC1(F)F)=O GMADLJSGNUJUCH-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N)=O LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- YGUAGAZZHWMLLO-UHFFFAOYSA-N CC(C)(C)OC(N(CCC1)C1C(CC1)CCN1C(OCc1ccccc1)=O)O Chemical compound CC(C)(C)OC(N(CCC1)C1C(CC1)CCN1C(OCc1ccccc1)=O)O YGUAGAZZHWMLLO-UHFFFAOYSA-N 0.000 description 1
- DMSLPGMAUARSMT-UHFFFAOYSA-N CC(C)(C)OC(N1C(C2CCNCC2)c2ccccc2C1)=O Chemical compound CC(C)(C)OC(N1C(C2CCNCC2)c2ccccc2C1)=O DMSLPGMAUARSMT-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N CC(C)(C)OC(NN)=O Chemical compound CC(C)(C)OC(NN)=O DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- BZCFPFKKLNRCPS-UHFFFAOYSA-N CC(N1CC(C2)(CC2N(CC2)CCC2=C2NCCC2)CC1)OC Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2=C2NCCC2)CC1)OC BZCFPFKKLNRCPS-UHFFFAOYSA-N 0.000 description 1
- NOVPYXFYTVFXEP-UHFFFAOYSA-N CC(N1CC(C2)(CC2N(CC2)CCC2C2NCCCC2)CC1)=C Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2C2NCCCC2)CC1)=C NOVPYXFYTVFXEP-UHFFFAOYSA-N 0.000 description 1
- JRAQWFWKNASODJ-GPJFCIFZSA-N CC(N1CC(C2)(CC2N(CC2)CCC2[C@H]2N(CC(F)(F)F)CCC2)CC1)=C Chemical compound CC(N1CC(C2)(CC2N(CC2)CCC2[C@H]2N(CC(F)(F)F)CCC2)CC1)=C JRAQWFWKNASODJ-GPJFCIFZSA-N 0.000 description 1
- SOFPALOKSUJISL-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2C2NCCC2)CC1)=O Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2C2NCCC2)CC1)=O SOFPALOKSUJISL-UHFFFAOYSA-N 0.000 description 1
- VTNPTBFHPQBIKL-OBXNSHGQSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2N(CC(C2)(F)F)[C@H]2C(NC)=O)CC1)=C Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2N(CC(C2)(F)F)[C@H]2C(NC)=O)CC1)=C VTNPTBFHPQBIKL-OBXNSHGQSA-N 0.000 description 1
- ZEYUGSOCURRXDF-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CC2)CCC2c2ncccc2C)CC1)=C Chemical compound CCOC(N1CC(C2)(CC2N(CC2)CCC2c2ncccc2C)CC1)=C ZEYUGSOCURRXDF-UHFFFAOYSA-N 0.000 description 1
- CGBLHVUOZYKMCK-UHFFFAOYSA-N CCOC(N1CC(C2)(CC2N(CCC2)CCCC22NCCC2)CC1)=O Chemical compound CCOC(N1CC(C2)(CC2N(CCC2)CCCC22NCCC2)CC1)=O CGBLHVUOZYKMCK-UHFFFAOYSA-N 0.000 description 1
- YAEGLMIBYIVZJZ-MRVPVSSYSA-N CC[C@H](CO1)N(C2CCNCC2)C1=O Chemical compound CC[C@H](CO1)N(C2CCNCC2)C1=O YAEGLMIBYIVZJZ-MRVPVSSYSA-N 0.000 description 1
- FMVBKBKOFVMNBG-UHFFFAOYSA-N CCc1nnc(C2CCN(C)CC2)[nH]1 Chemical compound CCc1nnc(C2CCN(C)CC2)[nH]1 FMVBKBKOFVMNBG-UHFFFAOYSA-N 0.000 description 1
- POTGJWFWPGMYQU-UHFFFAOYSA-N CN(CC1)CCC1N(CCCCC1)C1=O Chemical compound CN(CC1)CCC1N(CCCCC1)C1=O POTGJWFWPGMYQU-UHFFFAOYSA-N 0.000 description 1
- RPYSGPRTWAWWKK-UHFFFAOYSA-N COC(C(C1)NCC1(F)F)=O Chemical compound COC(C(C1)NCC1(F)F)=O RPYSGPRTWAWWKK-UHFFFAOYSA-N 0.000 description 1
- TUHWWSSACZIKGL-UHFFFAOYSA-N COC(C(CCCCC1)N1C1CCNCC1)=O Chemical compound COC(C(CCCCC1)N1C1CCNCC1)=O TUHWWSSACZIKGL-UHFFFAOYSA-N 0.000 description 1
- XZXVCMHKFUIDRV-LLVKDONJSA-N COC([C@@H](CCCC1)N1C1CCNCC1)=O Chemical compound COC([C@@H](CCCC1)N1C1CCNCC1)=O XZXVCMHKFUIDRV-LLVKDONJSA-N 0.000 description 1
- VVLRTXDYAWKZDG-UHFFFAOYSA-N Cc1nnn[n]1C1CCN(C)CC1 Chemical compound Cc1nnn[n]1C1CCN(C)CC1 VVLRTXDYAWKZDG-UHFFFAOYSA-N 0.000 description 1
- DRGIBGLITUBVOS-UHFFFAOYSA-N Cc1nnn[n]1C1CCNCC1 Chemical compound Cc1nnn[n]1C1CCNCC1 DRGIBGLITUBVOS-UHFFFAOYSA-N 0.000 description 1
- XPPFWBVTWIQNJV-UHFFFAOYSA-N O=S(OCC(F)(F)F)(S(F)(F)F)=O Chemical compound O=S(OCC(F)(F)F)(S(F)(F)F)=O XPPFWBVTWIQNJV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019201579A AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1402013.5A GB201402013D0 (en) | 2014-02-06 | 2014-02-06 | Pharmaceutical compounds |
| GB1402013.5 | 2014-02-06 | ||
| GB1416622.7 | 2014-09-19 | ||
| GBGB1416622.7A GB201416622D0 (en) | 2014-09-19 | 2014-09-19 | Pharmaceutical compounds |
| PCT/GB2015/050331 WO2015118342A1 (en) | 2014-02-06 | 2015-02-06 | Bicyclic aza compounds as muscarinic m1 receptor agonists. |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201579A Division AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015213900A1 AU2015213900A1 (en) | 2016-08-11 |
| AU2015213900B2 true AU2015213900B2 (en) | 2018-12-13 |
Family
ID=52465550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015213900A Active AU2015213900B2 (en) | 2014-02-06 | 2015-02-06 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2019201579A Active AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A Abandoned AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019201579A Active AU2019201579B2 (en) | 2014-02-06 | 2019-03-07 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
| AU2020277225A Abandoned AU2020277225A1 (en) | 2014-02-06 | 2020-11-26 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9670183B2 (enExample) |
| EP (4) | EP3102568B1 (enExample) |
| JP (7) | JP6479029B2 (enExample) |
| KR (1) | KR102352388B1 (enExample) |
| CN (2) | CN106458986B (enExample) |
| AU (3) | AU2015213900B2 (enExample) |
| BR (1) | BR112016017979B1 (enExample) |
| CA (1) | CA2938169C (enExample) |
| CL (1) | CL2016001983A1 (enExample) |
| CY (1) | CY1120834T1 (enExample) |
| DK (3) | DK4413985T3 (enExample) |
| ES (3) | ES3073836T3 (enExample) |
| FI (2) | FI4413985T3 (enExample) |
| HR (2) | HRP20241145T1 (enExample) |
| HU (1) | HUE068301T2 (enExample) |
| IL (1) | IL247117B (enExample) |
| LT (3) | LT4413985T (enExample) |
| MX (2) | MX371529B (enExample) |
| NZ (1) | NZ723103A (enExample) |
| PH (1) | PH12016501570B1 (enExample) |
| PL (2) | PL3102568T3 (enExample) |
| PT (3) | PT3102568T (enExample) |
| RS (3) | RS68268B1 (enExample) |
| RU (1) | RU2685230C2 (enExample) |
| SA (1) | SA516371614B1 (enExample) |
| SG (1) | SG11201606269WA (enExample) |
| SI (2) | SI3406609T1 (enExample) |
| SM (1) | SMT202400446T1 (enExample) |
| UA (1) | UA122121C2 (enExample) |
| WO (1) | WO2015118342A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2619829T3 (es) | 2011-11-18 | 2017-06-27 | Heptares Therapeutics Limited | Agonistas del receptor muscarínico M1 |
| DK2968297T3 (en) | 2013-03-15 | 2019-01-07 | Verseon Inc | MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS |
| RU2685230C2 (ru) | 2014-02-06 | 2019-04-17 | Хептарес Терапьютикс Лимитед | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов |
| GB201404922D0 (en) * | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| ES2931460T3 (es) * | 2015-02-27 | 2022-12-29 | Verseon Int Corporation | Compuestos de pirazol sustituido como inhibidores de serina proteasa |
| GB201504675D0 (en) | 2015-03-19 | 2015-05-06 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201513740D0 (en) * | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonist |
| GB201519352D0 (en) * | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| WO2017107089A1 (en) | 2015-12-23 | 2017-06-29 | Merck Sharp & Dohme Corp. | 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor |
| EP3394061B1 (en) | 2015-12-23 | 2020-03-11 | Merck Sharp & Dohme Corp. | 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor |
| PL3478679T3 (pl) * | 2016-07-01 | 2021-10-25 | Pfizer Inc. | Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych |
| GB201617454D0 (en) * | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| GB201709652D0 (en) * | 2017-06-16 | 2017-08-02 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| EP3643703A4 (en) | 2017-06-21 | 2020-12-23 | Daiichi Sankyo Co., Ltd. | EP300 / CREBBP INHIBITOR |
| WO2019000237A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000238A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| WO2019000236A1 (en) | 2017-06-27 | 2019-01-03 | Merck Sharp & Dohme Corp. | ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR |
| EP3651762B1 (en) | 2017-07-12 | 2024-07-03 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN110944999A (zh) * | 2017-08-01 | 2020-03-31 | 勃林格殷格翰国际有限公司 | 中间体化合物和方法 |
| JP7270989B2 (ja) | 2017-10-20 | 2023-05-11 | ヴァンダービルト ユニバーシティー | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
| US10501483B2 (en) | 2017-10-24 | 2019-12-10 | Allergan, Inc. | Enamines and diastereo-selective reduction of enamines |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
| EP3768669B1 (en) * | 2018-03-23 | 2023-01-25 | Pfizer Inc. | Piperazine azaspiro derivaves |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810245D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| UY38906A (es) * | 2019-10-09 | 2021-05-31 | Novartis Ag | Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos |
| PH12022550860A1 (en) * | 2019-10-09 | 2023-06-14 | Novartis Ag | 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists |
| US12486250B2 (en) | 2019-12-06 | 2025-12-02 | Neurocrine Biosciences, Inc. | Muscarinic receptor 4 antagonists and methods of use |
| TWI889751B (zh) * | 2020-02-05 | 2025-07-11 | 美商紐羅克里生物科學有限公司 | 蕈毒受體4拮抗劑及使用方法 |
| US11912705B2 (en) * | 2020-08-20 | 2024-02-27 | The Corporation Of Mercer University | Cathinone derivatives, pharmaceutical formulations, and methods |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CR20250069A (es) | 2022-08-04 | 2025-05-26 | Nxera Pharma Uk Ltd | Formas cristalinas y sales de un agonista del receptor muscarínico |
| KR20250086639A (ko) * | 2022-09-16 | 2025-06-13 | 세레벨 쎄라퓨틱스, 엘엘씨 | M4 활성제/조절제 및 이의 용도 |
| AU2024208125A1 (en) * | 2023-01-12 | 2025-07-10 | Cerevel Therapeutics, Llc | Spiro derivatives as m4 activators/modulators and uses thereof |
| JP2026503599A (ja) | 2023-01-24 | 2026-01-29 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 重水素化化合物 |
| CN116496195A (zh) * | 2023-05-10 | 2023-07-28 | 南京优氟医药科技有限公司 | 一种（r）-4,4-二氟代吡咯烷-2-羧酸的制备方法 |
| KR20260046441A (ko) | 2023-08-03 | 2026-04-07 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 합성 방법 |
| WO2026050225A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Method of treating a neurological or psychiatric disease or disorder |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
| TW202615016A (zh) | 2024-08-27 | 2026-04-16 | 美商紐羅克里生物科學有限公司 | 醫藥調配物 |
| TW202615015A (zh) | 2024-08-27 | 2026-04-16 | 美商紐羅克里生物科學有限公司 | 特定毒蕈鹼受體激動劑之投與方法 |
| WO2026050238A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist for use in the treatment of a neurological or psychiatric disorder |
| TW202619719A (zh) | 2024-08-27 | 2026-05-16 | 美商紐羅克里生物科學有限公司 | 治療方法 |
| TW202619712A (zh) * | 2024-09-09 | 2026-05-16 | 大陸商翼思生物醫藥（蘇州）有限公司 | 5-ht2a受體激動劑及m4活化劑之組合及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054911A1 (en) * | 2005-03-28 | 2007-03-08 | Ioana Drutu | Muscarinic modulators |
| WO2007100670A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| CN101874020A (zh) * | 2007-09-11 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 作为毒蕈碱受体激动剂的哌啶衍生物 |
| WO2013072705A1 (en) * | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852029A (en) | 1990-04-10 | 1998-12-22 | Israel Institute For Biological Research | Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity |
| AU2206699A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| US7164024B2 (en) * | 2001-04-20 | 2007-01-16 | Banyu Pharmaceutical Co., Ltd. | Benzimidazolone derivatives |
| AU2005249494A1 (en) * | 2004-05-28 | 2005-12-15 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| CA2634456A1 (en) | 2005-12-22 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| US8003660B2 (en) | 2006-02-22 | 2011-08-23 | Vertex Pharmaceuticals Incorporated | Modulators of muscarinic receptors |
| WO2007106670A2 (en) * | 2006-03-03 | 2007-09-20 | Novartis Ag | N-formyl hydroxylamine compounds |
| GB0706188D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| AU2009309988A1 (en) | 2008-10-29 | 2010-05-06 | Grunenthal Gmbh | Substituted spiroamines |
| FR2945531A1 (fr) | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| WO2012020813A1 (ja) * | 2010-08-10 | 2012-02-16 | 大日本住友製薬株式会社 | 縮環ピロリジン誘導体 |
| HK1214815A1 (zh) | 2013-04-30 | 2016-08-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Zeste增强子同源物2的抑制剂 |
| RU2685230C2 (ru) * | 2014-02-06 | 2019-04-17 | Хептарес Терапьютикс Лимитед | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов |
| CR20160400A (es) | 2014-02-06 | 2016-11-07 | Riboscience Llc | Derivados de nucleosido sustituidos con 4´-difluorometilo como inhibidores de la replicación de arn de la influenza |
| PL3102572T3 (pl) | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Pochodne sulfamoilopirolamidu i ich zastosowanie jako leki do leczenia wirusowego zapalenia wątroby typu B |
| WO2016042084A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 inhibitors |
| HUE062424T2 (hu) | 2014-09-19 | 2023-11-28 | Forma Therapeutics Inc | Piridin-2(1H)-on kinolinon származékok mint mutáns izocitrát dehidrogenáz inhibitorok |
| EA033697B1 (ru) | 2014-09-19 | 2019-11-18 | Glaxosmithkline Ip Dev Ltd | Активаторы растворимой гуанилатциклазы и их применение |
-
2015
- 2015-02-06 RU RU2016133684A patent/RU2685230C2/ru active
- 2015-02-06 MX MX2016010322A patent/MX371529B/es active IP Right Grant
- 2015-02-06 HU HUE18179258A patent/HUE068301T2/hu unknown
- 2015-02-06 BR BR112016017979-0A patent/BR112016017979B1/pt active IP Right Grant
- 2015-02-06 FI FIEP24177415.7T patent/FI4413985T3/fi active
- 2015-02-06 FI FIEP18179258.1T patent/FI3406609T3/fi active
- 2015-02-06 EP EP15703826.6A patent/EP3102568B1/en active Active
- 2015-02-06 LT LTEP24177415.7T patent/LT4413985T/lt unknown
- 2015-02-06 RS RS20260630A patent/RS68268B1/en unknown
- 2015-02-06 US US15/117,018 patent/US9670183B2/en active Active
- 2015-02-06 CN CN201580017993.6A patent/CN106458986B/zh active Active
- 2015-02-06 KR KR1020167024572A patent/KR102352388B1/ko active Active
- 2015-02-06 ES ES24177415T patent/ES3073836T3/es active Active
- 2015-02-06 AU AU2015213900A patent/AU2015213900B2/en active Active
- 2015-02-06 LT LTEP18179258.1T patent/LT3406609T/lt unknown
- 2015-02-06 HR HRP20241145TT patent/HRP20241145T1/hr unknown
- 2015-02-06 PT PT15703826T patent/PT3102568T/pt unknown
- 2015-02-06 NZ NZ723103A patent/NZ723103A/en unknown
- 2015-02-06 PL PL15703826T patent/PL3102568T3/pl unknown
- 2015-02-06 UA UAA201609185A patent/UA122121C2/uk unknown
- 2015-02-06 PL PL18179258.1T patent/PL3406609T3/pl unknown
- 2015-02-06 JP JP2016550483A patent/JP6479029B2/ja active Active
- 2015-02-06 LT LTEP15703826.6T patent/LT3102568T/lt unknown
- 2015-02-06 SG SG11201606269WA patent/SG11201606269WA/en unknown
- 2015-02-06 PT PT181792581T patent/PT3406609T/pt unknown
- 2015-02-06 DK DK24177415.7T patent/DK4413985T3/da active
- 2015-02-06 CN CN201910003375.6A patent/CN109851610B/zh active Active
- 2015-02-06 SI SI201532034T patent/SI3406609T1/sl unknown
- 2015-02-06 PT PT241774157T patent/PT4413985T/pt unknown
- 2015-02-06 CA CA2938169A patent/CA2938169C/en active Active
- 2015-02-06 MX MX2020001236A patent/MX393637B/es unknown
- 2015-02-06 ES ES18179258T patent/ES2986327T3/es active Active
- 2015-02-06 SM SM20240446T patent/SMT202400446T1/it unknown
- 2015-02-06 RS RS20240960A patent/RS65894B1/sr unknown
- 2015-02-06 ES ES15703826.6T patent/ES2688548T3/es active Active
- 2015-02-06 DK DK15703826.6T patent/DK3102568T3/en active
- 2015-02-06 DK DK18179258.1T patent/DK3406609T3/da active
- 2015-02-06 EP EP18179258.1A patent/EP3406609B1/en active Active
- 2015-02-06 EP EP26156152.6A patent/EP4714446A3/en active Pending
- 2015-02-06 EP EP24177415.7A patent/EP4413985B1/en active Active
- 2015-02-06 HR HRP20181499TT patent/HRP20181499T1/hr unknown
- 2015-02-06 SI SI201530399T patent/SI3102568T1/sl unknown
- 2015-02-06 RS RS20181127A patent/RS57843B1/sr unknown
- 2015-02-06 WO PCT/GB2015/050331 patent/WO2015118342A1/en not_active Ceased
-
2016
- 2016-08-04 IL IL247117A patent/IL247117B/en active IP Right Grant
- 2016-08-04 SA SA516371614A patent/SA516371614B1/ar unknown
- 2016-08-05 CL CL2016001983A patent/CL2016001983A1/es unknown
- 2016-08-08 PH PH12016501570A patent/PH12016501570B1/en unknown
-
2017
- 2017-05-10 US US15/591,605 patent/US9926297B2/en active Active
-
2018
- 2018-02-22 US US15/902,537 patent/US10196380B2/en active Active
- 2018-09-27 CY CY181100996T patent/CY1120834T1/el unknown
- 2018-12-12 US US16/217,570 patent/US10385039B2/en active Active
-
2019
- 2019-02-01 JP JP2019017086A patent/JP6774513B2/ja active Active
- 2019-03-07 AU AU2019201579A patent/AU2019201579B2/en active Active
- 2019-07-01 US US16/459,179 patent/US10689368B2/en active Active
-
2020
- 2020-06-17 US US16/904,099 patent/US10961225B2/en active Active
- 2020-10-05 JP JP2020168341A patent/JP2021006571A/ja not_active Withdrawn
- 2020-11-26 AU AU2020277225A patent/AU2020277225A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060030A patent/JP7652829B2/ja active Active
- 2023-05-02 JP JP2023076024A patent/JP7652832B2/ja active Active
- 2023-05-02 JP JP2023076025A patent/JP7652833B2/ja active Active
-
2025
- 2025-03-14 JP JP2025041135A patent/JP2025085736A/ja active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070054911A1 (en) * | 2005-03-28 | 2007-03-08 | Ioana Drutu | Muscarinic modulators |
| WO2007100670A1 (en) * | 2006-02-22 | 2007-09-07 | Vertex Pharmaceuticals Incorporated | Spiro condensed piperidnes as modulators of muscarinic receptors |
| CN101874020A (zh) * | 2007-09-11 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 作为毒蕈碱受体激动剂的哌啶衍生物 |
| WO2013072705A1 (en) * | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
| WO2014045031A1 (en) * | 2012-09-18 | 2014-03-27 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
| US9266857B2 (en) * | 2012-09-18 | 2016-02-23 | Heptares Therapeutics Limited | Bicyclic AZA compounds as muscarinic M1 receptor agonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10961225B2 (en) | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | |
| CA2994143C (en) | Muscarinic agonists | |
| HK40114593A (en) | Pharmaceutical compounds | |
| RU2811601C1 (ru) | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов | |
| RU2811601C9 (ru) | Бициклические азотсодержащие соединения как агонисты М1 мускариновых рецепторов | |
| HK1231473B (en) | Bicyclic aza compounds as muscarinic m1 receptor agonists | |
| HK40007500A (en) | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| HB | Alteration of name in register |
Owner name: NXERA PHARMA UK LIMITED Free format text: FORMER NAME(S): HEPTARES THERAPEUTICS LIMITED |